Ladero JM et al. - The “12-week stopping rule” includes two different categories of responders considered candidates for maintained therapy, but the probability of obtaining SVR is very low in patients with HCV-RNA that is still detectable at this time of treatment. Author suggest that, in these partial responders, the prolongation of therapy should be decided on an individual basis.
See all
